Hiv Vaccine Trials Network
HVTN is the world's largest publicly funded collaboration dedicated to evaluating vaccines to prevent HIV/AIDS. It advances research in vaccinology, social sciences, immunology, and also works on tuberculosis and COVID-19 vaccines. The network conducts all phases of clinical trials to develop a safe and effective HIV vaccine, involving community engagement, scientific research, and global collaboration. It is headquartered at Fred Hutchinson Cancer Center in Seattle, WA, and collaborates with research sites, laboratories, and community stakeholders worldwide.
Industries
Nr. of Employees
medium (51-250)
Hiv Vaccine Trials Network
1100 Fairview Ave. N., P.O. Box 19024, Seattle, WA 98109-1024
Services
Operational management and conduct of Phase 1–3 preventive vaccine and monoclonal antibody trials, including site coordination, participant enrollment, and visit completion monitoring.
Coordinated laboratory operations including assay development, qualification, standardized testing, specimen processing, and repository management for immunologic and virologic endpoints.
Statistical design, data management, case report processing, immune correlates analysis, and specialized methods (adaptive designs, sieve analysis) provided by a central Statistical and Data Management Center.
Development and delivery of community engagement strategies, recruitment plans, retention programs, community advisory board facilitation, and public education materials following Good Participatory Practice principles.
Organization of investigator conferences, early-stage investigator meetings, travel awards and mentorship programs to support translational research capacity and career development.
Operational management and conduct of Phase 1–3 preventive vaccine and monoclonal antibody trials, including site coordination, participant enrollment, and visit completion monitoring.
Coordinated laboratory operations including assay development, qualification, standardized testing, specimen processing, and repository management for immunologic and virologic endpoints.
Statistical design, data management, case report processing, immune correlates analysis, and specialized methods (adaptive designs, sieve analysis) provided by a central Statistical and Data Management Center.
Development and delivery of community engagement strategies, recruitment plans, retention programs, community advisory board facilitation, and public education materials following Good Participatory Practice principles.
Organization of investigator conferences, early-stage investigator meetings, travel awards and mentorship programs to support translational research capacity and career development.
Expertise Areas
- Clinical trial management (all phases)
- Vaccine immunology and broadly neutralizing antibody research
- Biostatistics and trial design for vaccine efficacy studies
- Assay development and laboratory validation
Key Technologies
- ELISpot assays
- Enzyme-linked immunosorbent assays (ELISA)
- Neutralization assays (virus neutralization)
- Multiplex binding antibody assays
News & Updates
The HVTN exceeded national standards for clinical research, demonstrating superior efficiency in protocol development, study opening, and volunteer enrollment, with detailed performance metrics reported for 2023-2024.
The HVTN 702 trial, a large HIV vaccine efficacy study in South Africa, was stopped early after interim analysis showed it was not effective.
Highlights include completion of seven phase 1 studies of broadly neutralizing antibodies, development of vaccine strategies, and contributions to understanding immune responses and correlates of protection.
Renewal of NIH funding for 7 years
HVTN successfully renewed its grant and funding from the NIH in 2021, supporting ongoing research and trials.
Development of new statistical methods for HIV vaccine evaluation
HVTN scientists developed innovative statistical and analytical methods to evaluate immune responses and vaccine efficacy.
Establishment of laboratory and community research infrastructure
HVTN established state-of-the-art laboratories and community engagement programs across multiple countries.
The HVTN exceeded national standards for clinical research, demonstrating superior efficiency in protocol development, study opening, and volunteer enrollment, with detailed performance metrics reported for 2023-2024.
The HVTN 702 trial, a large HIV vaccine efficacy study in South Africa, was stopped early after interim analysis showed it was not effective.
Highlights include completion of seven phase 1 studies of broadly neutralizing antibodies, development of vaccine strategies, and contributions to understanding immune responses and correlates of protection.
Renewal of NIH funding for 7 years
HVTN successfully renewed its grant and funding from the NIH in 2021, supporting ongoing research and trials.
Development of new statistical methods for HIV vaccine evaluation
HVTN scientists developed innovative statistical and analytical methods to evaluate immune responses and vaccine efficacy.
Establishment of laboratory and community research infrastructure
HVTN established state-of-the-art laboratories and community engagement programs across multiple countries.